OBJECTIVES: To describe and analyse pricing and reimbursement (P&R) process times of medicines that have received marketing authorisation (MA) between years 2005 and 2015, subsequently accepted to reimbursement system in Finland. A comparison between two time periods (2005-2010/2011-2015) and two groups of products (oncological/other) was conducted. METHODS:  Products that received MA and reimbursement at given years were identified from public sources. Biosimilars, generics, new indications and combination products were excluded from the analysis based on their special status in the Finnish P&R process. RESULTS: A total of 145 products were included into the analysis. In 2005-2010 a total of 14 oncological and 65 non-oncological products were identified. Time to basic reimbursement from MA was 13.9 and 25.9 months (median 11.5 and 17.0 months), respectively, and time to special reimbursement 36.0 and 48.4 months (median 37.0 and 41.5 months), respectively. In 2011-2015 a total of 24 oncological and 42 non-oncological products were identified. Time to basic reimbursement from MA was 20.9 and 15.9 months (median 17.0 and 12.5 months), respectively, and time to special reimbursement 33.7 and 35.9 months (median 34.5 and 33.0 months), respectively. Furthermore, a similar trend was observed in time to basic reimbursement from placing the product in the market. CONCLUSIONS:  The data shows that the share of oncological products has doubled (from 18% to 36%) from 2005-2010 to 2011-2015, and suggests that time to reimbursement for oncological products has increased significantly and decreased for non-oncological products. There seems to be a clear paradigm shift in P&R decision making regarding oncological products in Finland. The explanation may lie in the combination of more strict interpretation of reimbursement criteria, increased share of oncological products entering the market and their budget impact.